| __timestamp | Iovance Biotherapeutics, Inc. | Travere Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 2704597 | 47795223 |
| Thursday, January 1, 2015 | 15470000 | 50426000 |
| Friday, January 1, 2016 | 28037000 | 70853000 |
| Sunday, January 1, 2017 | 71615000 | 78168000 |
| Monday, January 1, 2018 | 99828000 | 123757000 |
| Tuesday, January 1, 2019 | 166023000 | 140963000 |
| Wednesday, January 1, 2020 | 201727000 | 131773000 |
| Friday, January 1, 2021 | 259039000 | 210328000 |
| Saturday, January 1, 2022 | 294781000 | 235780000 |
| Sunday, January 1, 2023 | 344077000 | 244990000 |
Data in motion
In the ever-evolving world of biotechnology, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, Iovance Biotherapeutics, Inc. and Travere Therapeutics, Inc. have demonstrated significant growth in their R&D investments.
From 2014 to 2023, Iovance Biotherapeutics increased its R&D expenses by an impressive 12,600%, reflecting its dedication to pioneering cancer immunotherapies. By 2023, their R&D spending reached a peak, showcasing a strategic focus on advancing their clinical pipeline.
Similarly, Travere Therapeutics has shown a robust 413% increase in R&D spending over the same period. This growth underscores their commitment to developing treatments for rare diseases, with a notable surge in investment from 2021 onwards.
These trends highlight the dynamic nature of the biotech industry, where strategic R&D investments are pivotal for future breakthroughs.
Eli Lilly and Company or Travere Therapeutics, Inc.: Who Invests More in Innovation?
Comparing Innovation Spending: Sanofi and Travere Therapeutics, Inc.
Research and Development Investment: Gilead Sciences, Inc. vs Iovance Biotherapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Incyte Corporation and Travere Therapeutics, Inc.
Comparing Innovation Spending: Viatris Inc. and Iovance Biotherapeutics, Inc.
Research and Development: Comparing Key Metrics for Summit Therapeutics Inc. and Travere Therapeutics, Inc.
Comparing Innovation Spending: Axsome Therapeutics, Inc. and Iovance Biotherapeutics, Inc.
Comparing Innovation Spending: Ultragenyx Pharmaceutical Inc. and Travere Therapeutics, Inc.
Comparing Innovation Spending: CymaBay Therapeutics, Inc. and Iovance Biotherapeutics, Inc.
Comparing Innovation Spending: CRISPR Therapeutics AG and Travere Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for ACADIA Pharmaceuticals Inc. and Iovance Biotherapeutics, Inc.
Research and Development: Comparing Key Metrics for Amicus Therapeutics, Inc. and Travere Therapeutics, Inc.